Cargando…

Pre-clinical activity of the oral DNA-PK inhibitor, peposertib (M3814), combined with radiation in xenograft models of cervical cancer

DNA-dependent protein kinase (DNA-PK) plays a crucial role in repair of DNA double-strand breaks by facilitating non-homologous end-joining. Inhibitors of DNA-PK have the potential to block DNA repair and enhance DNA-damaging agents. Peposertib (M3814) is a DNA-PK inhibitor that has shown preclinica...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gordhandas, Sushmita B., Manning-Geist, Beryl, Henson, Christina, Iyer, Gopa, Gardner, Ginger J., Sonoda, Yukio, Moore, Kathleen N., Aghajanian, Carol, Chui, M. Herman, Grisham, Rachel N.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8770623/ https://www.ncbi.nlm.nih.gov/pubmed/35046420 http://dx.doi.org/10.1038/s41598-021-04618-5

Ejemplares similares

Activity of M3814, an Oral DNA-PK Inhibitor, In Combination with Topoisomerase II Inhibitors in Ovarian Cancer Models
por: Wise, Hannah C., et al.
Publicado: (2019)

A first-in-man phase 1 study of the DNA-dependent protein kinase inhibitor peposertib (formerly M3814) in patients with advanced solid tumours
por: van Bussel, Mark T. J., et al.
Publicado: (2020)

DNA-PK inhibition by M3814 enhances chemosensitivity in non-small cell lung cancer
por: Wang, Manni, et al.
Publicado: (2021)

DNA-PK Inhibitor, M3814, as a New Combination Partner of Mylotarg in the Treatment of Acute Myeloid Leukemia
por: Carr, Michael I., et al.
Publicado: (2020)

M3814, a DNA-PK Inhibitor, Modulates ABCG2-Mediated Multidrug Resistance in Lung Cancer Cells
por: Wu, Zhuo-Xun, et al.
Publicado: (2020)

DNA-PK inhibitor peposertib enhances p53-dependent cytotoxicity of DNA double-strand break inducing therapy in acute leukemia
por: Haines, Eric, et al.
Publicado: (2021)

DNA-PK Inhibitor Peposertib Amplifies Radiation-Induced Inflammatory Micronucleation and Enhances TGFβ/PD-L1 Targeted Cancer Immunotherapy
por: Carr, Michael I., et al.
Publicado: (2022)

Quaternary and beyond cytoreduction: An updated and expanded analysis
por: Manning-Geist, Beryl L., et al.
Publicado: (2021)

Prevention over screening for ovarian cancer in patients with high-risk germline mutations: Misinterpreting the findings of ALDO
por: Manning-Geist, Beryl L., et al.
Publicado: (2023)

Comment on Kronenfeld et al. Clinical Outcomes for Primary and Radiation-Associated Angiosarcoma of the Breast with Multimodal Treatment: Long-Term Survival Is Achievable. Cancers 2021, 13, 3814
por: Notter, Markus, et al.
Publicado: (2021)

Retreatment with carboplatin and paclitaxel for recurrent endometrial cancer: A retrospective study of the Memorial Sloan Kettering Cancer Center experience
por: Rubinstein, Maria, et al.
Publicado: (2019)

Assessment of wound perfusion with near-infrared angiography: A prospective feasibility study
por: Manning-Geist, Beryl L., et al.
Publicado: (2022)

Brain metastasis in advanced serous borderline tumor of the ovary: A case presentation()
por: Martin, Madhuri, et al.
Publicado: (2017)

Characterization of prickle isoform-specific pk (pk1) and pk (sple1) mutations in Drosophila melanogaster
por: Lilienthal, Anthony J, et al.
Publicado: (2022)

Characteristics and survival of ovarian cancer patients treated with neoadjuvant chemotherapy but not undergoing interval debulking surgery
por: Liu, Ying L., et al.
Publicado: (2019)

A double‐hit High‐grade B‐cell lymphoma with three‐way translocation t(3;8;14)(q27;q24;q32) involving BCL6, MYC, and IGH
por: De Paoli, Elena, et al.
Publicado: (2018)

The use of fertility preservation services for cancer patients: a single institution experience
por: McCarter, Kelly, et al.
Publicado: (2022)

Benchmarking pK(a )prediction
por: Davies, Matthew N, et al.
Publicado: (2006)

Small cell neuroendocrine carcinoma of the cervix: Analysis of prognostic factors and patterns of metastasis
por: Gordhandas, Sushmita, et al.
Publicado: (2022)

Joint analysis of PK and immunogenicity outcomes using factorization model − a powerful approach for PK similarity study
por: Haliduola, Halimu N., et al.
Publicado: (2022)

Acute Myeloid Leukemia Presenting as Myeloid Sarcoma with a Predisposition to the Gynecologic Tract
por: Kahn, Ryan M., et al.
Publicado: (2019)

Emerging biomarkers in urothelial carcinoma: Challenges and opportunities
por: Andreatos, Nikolaos, et al.
Publicado: (2020)

Pre-clinical Stress Management Workshops Increase Medical Students’ Knowledge and Self-awareness of Coping with Stress
por: Manning-Geist, Beryl, et al.
Publicado: (2019)

Cervical carcinoma in the setting of uterovaginal prolapse: comparing standard versus tailored management
por: Kahn, Ryan M, et al.
Publicado: (2020)

Conocimientos de la hipertensión: Health beliefs about hypertension in an under-resourced community in the Dominican Republic
por: Abrams, Jasmine A., et al.
Publicado: (2020)

Complete Genome Sequence of the Pokeweed Mosaic Virus (PkMV)-New Jersey Isolate and Its Comparison to PkMV-MD and PkMV-PA
por: Di, Rong
Publicado: (2016)

Model‐Informed Drug Development for Antimicrobials: Translational PK and PK/PD Modeling to Predict an Efficacious Human Dose for Apramycin
por: Sou, Tomás, et al.
Publicado: (2020)

In silico pK(a) prediction
por: Körner, Robert, et al.
Publicado: (2012)

Ceftobiprole: pharmacokinetics and PK/PD profile
por: Azanza Perea, José Ramón, et al.
Publicado: (2019)

In vitro dynamic pharmacokinetic/pharmacodynamic(PK/PD) modeling and PK/PD cutoff of cefquinome against Haemophilus parasuis
por: Xiao, Xia, et al.
Publicado: (2015)

1321. Population Pharmacokinetic (PK) and Pharmacokinetic/Pharmacodynamic (PK/PD) Target Attainment Analyses for Dalbavancin in Pediatric Patients
por: Carrothers, Timothy J, et al.
Publicado: (2020)

Population PK and Semimechanistic PK/PD Modeling and Simulation of Relugolix Effects on Testosterone Suppression in Men with Prostate Cancer
por: Lee, Tien‐Yi, et al.
Publicado: (2022)

Phase I Study of a Multivalent WT1 Peptide Vaccine (Galinpepimut-S) in Combination with Nivolumab in Patients with WT1-Expressing Ovarian Cancer in Second or Third Remission
por: Manning-Geist, Beryl L., et al.
Publicado: (2023)

PK-sensitive PrP(Sc) Is Infectious and Shares Basic Structural Features with PK-resistant PrP(Sc)
por: Sajnani, Gustavo, et al.
Publicado: (2012)

Concerns about pharmacokinetic (PK) and pharmacokinetic-pharmacodynamic (PK-PD) studies in the new therapeutic area of COVID-19 infection
por: Venisse, Nicolas, et al.
Publicado: (2020)

In vivo Pharmacokinetic and Pharmacodynamic (PK/PD) Modeling and Establishment of the PK/PD Cutoff of Florfenicol Against Pasteurella multocida in Ducks
por: Xiao, Xia, et al.
Publicado: (2021)

Depletion of pyruvate kinase (PK) activity causes glycolytic intermediate imbalances and reveals a PK-TXNIP regulatory axis
por: Nieborak, Anna, et al.
Publicado: (2023)

Ionization Constants pK(a) of Cardiolipin
por: Olofsson, Gerd, et al.
Publicado: (2013)

DNA-PK as an Emerging Therapeutic Target in Cancer
por: Mohiuddin, Ismail S., et al.
Publicado: (2019)

Machine learning meets pK (a)
por: Baltruschat, Marcel, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_a1a5j9h2mvg4eg7he94snv1ids